Mutant NRASQ61 shares signaling similarities across various cancer types - potential implications for future therapies

Oncotarget

Volumn 5, Issue 17, 2014, Pages 7936-7944

  Vujic, Igor ^a,b   Posch, Christian ^a,b   Sanlorenzo, Martina ^a,c   Yen, Adam J ^a   Tsumura, Aaron ^a   Kwong, Andrew ^a   Feichtenschlager, Valentin ^b   Lai, Kevin ^a   Arneson, Douglas V ^a   Rappersberger, Klemens ^b   Ortiz Urda, Susana M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Universitatsklinik fur Dermatologie   (Austria)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

Combination therapy; Lung cancer; Neuroblastoma; NRAS

Indexed keywords

4 [2 (4 AMINO 1,2,5 OXADIAZOL 3 YL) 1 ETHYL 7 (3 PIPERIDINYLMETHOXY) 1H IMIDAZO[4,5 C]PYRIDIN 4 YL] 2 METHYL 3 BUTYN 2 OL; AZD 8055; DACTOLISIB; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; OMIPALISIB; PALBOCICLIB; PHOSPHATIDYLINOSITOL 3 KINASE; PICTILISIB; PROTEIN KINASE B; PROTEIN S6; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; GUANOSINE TRIPHOSPHATASE; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER THERAPY; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; GENE MUTATION; IN VITRO STUDY; LUNG CANCER; NEUROBLASTOMA; ONCOGENE N RAS; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; CELL SURVIVAL; DNA MUTATIONAL ANALYSIS; DRUG EFFECTS; DRUG RESISTANCE; GENETIC TRANSFECTION; GENETICS; HUMAN; IMMUNOBLOTTING; MUTATION; NEOPLASM; POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GTP PHOSPHOHYDROLASES; HUMANS; IMMUNOBLOTTING; MEMBRANE PROTEINS; MUTATION; NEOPLASMS; POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84907485891     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2326     Document Type: Article

References (36)

1. Repasky GA, Chenette EJ, Der CJ. Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis? Trends in Cell Biology. 2004; 14: 639-47.
2. Kratz CP, Schubbert S, Bollag G, Niemeyer CM, Shannon KM, Zenker M. Germline Mutations in Components of the Ras Signaling Pathway in Noonan Syndrome and Related Disorders. Cell Cycle. 2006; 5: 1607-11.
3. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nature Reviews Cancer. 2007; 7: 295-308.
4. Bos JL. ras oncogenes in human cancer: a review. Cancer Research. 1989; 49: 4682-9.
5. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Broecker EV, LeBoit PE, Pinkel D, Bastian B. Distinct Sets of Genetic Alterations in Melanoma. New England Journal of Medicine. 2005; 353: 2135-47.
6. Colombino M, Lissia A, Capone M, Giorgi VD, Massi D, Stanganelli I, Fonsatti E, Maio M, Botti G, Caraco C, Mozzillo N, Ascierto P, Cossu A, Palmieri G. Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma. Journal of Translational Medicine. 2013; 11: 202.
7. Grimaldi AM, Simeone E, Ascierto PA. The role of MEK inhibitors in the treatment of metastatic melanoma. Current Opinion in Oncology. 2014; 26:196-203.
8. Surveillance, Epidemiology, and End Results Program [Internet]. [cited 2014 Mar 31]. Available from: http://seer.cancer.gov/
9. Howlader N. SEER Cancer Statistics Review 1975-2010 [Internet]. [cited 2013 Sep 14]. Available from: http://seer.cancer.gov/csr/1975_2010/
10. Ohashi K, Sequist LV, Arcila ME, Lovly CM, Chen X, Rudin CM, Moran T, Camidge DR, Vnencak-Jones CL, Berry L, Pan Y, Sasaki H, Engelman JA et al. Characteristics of Lung Cancers Harboring NRAS Mutations. Clinical Cancer Research. 2013; 19:2584-91.
11. Comprehensive Cancer Information-National Cancer Institute [Internet]. [cited 2014 Mar 31]. Available from: http://www.cancer.gov/
12. Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, Carter SL, Cibulskis K, Hanna M, Kiezun A, Kim J, Lawrence MS, Lichenstein L, et al. The genetic landscape of high-risk neuroblastoma. Nature Genetics. 2013; 45: 279-84.
13. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncology. 2010; 11: 753-62.
14. Irahara N, Baba Y, Nosho K, Shima K, Yan L, Dias-Santagata D, Iafrate AJ, Fuchs CS, Haigis KM, Ogino S. NRAS mutations are rare in colorectal cancer. Diagnostic Molecular Pathology. 2010; 19: 157-63.
15. Janku F, Lee JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Luthra R, Garrido-Laguna I, Kurzrock R. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS ONE. 2011; 6: e22769.
16. Vaughn CP, Zobell SD, Furtado LV, Baker CL, Samowitz WS. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer. 2011; 50: 307-12.
17. COSMIC: Catalogue Of Somatic Mutations In Cancer [Internet]. [cited 2014 Mar 31]. Available from: http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/
18. Bacher U, Haferlach T, Schoch C, Kern W, Schnittger S. Implications of NRAS mutations in AML: a study of 2502 patients. Blood. 2006; 107: 3847-53.
19. Posch C, Moslehi H, Feeney L, Green GA, Ebaee A, Feichtenschlager V, Chong K, Peng L, Dimon MT, Phillips T, Daud AI, McCalmont TH, LeBoit PE, Ortiz-Urda S. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proceedings of the National Academy of Sciences. 2013; 110: 4015-20.
20. Han EK-H, Leverson JD, McGonigal T, Shah OJ, Woods KW, Hunter T,Giranda VL, Luo Y. Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition. Oncogene. 2007; 26: 5655-61.
21. Heerding DA, Rhodes N, Leber JD, Clark TJ, Keenan RM, Lafrance LV, Lil M, Safonov IG, Takata DT, Venslavsky JW, Yamashita DS, Choudhry AE, Copeland RA, et al. Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase. Journal of Medicinal Chemistry. 2008; 51: 5663-79.
22. Lowy DR, Willumsen BM. Function and Regulation of RAS. Annual Review of Biochemistry. 1993; 62: 851-91.
23. Okuzumi T, Fiedler D, Zhang C, Gray DC, Aizenstein B, Hoffman R, Shokat KM. Inhibitor Hijacking of Akt Activation. Nature Chemical Biology. 2009; 5:484-93.
24. Giehl K. Oncogenic Ras in tumour progression and metastasis. Biological Chemistry. 2005; 386: 193-205.
25. Jaiswal BS, Janakiraman V, Kljavin NM, Eastham-Anderson J, Cupp JE, Liang Y, Davis DP, Hoeflilch KP, Seshagiri S. Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors. PLoS ONE. 2009; 4: e5717.
26. Britten CD. PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types. Cancer Chemotherapy and Pharmacology. 2013; 71: 1395-409.
27. Downward J. Targeting RAS signalling pathways in cancer therapy. Nature Review Cancer. 2003; 3: 11-22.
28. Rader J, Russell MR, Hart LS, Nakazawa MS, Belcastro LT, Martinez D, Li Y, Carpenter EL, Attiyeh EF, Diskin SJ, Kim S, Parasuraman S, Capongiro G, et al. Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma. Clinical Cancer Research. 2013; 19: 6173-82.
29. Eskandarpour M, Huang F, Reeves KA, Clark E, Hansson J. Oncogenic NRAS has multiple effects on the malignant phenotype of human melanoma cells cultured in vitro. International Journal of Cancer. 2009; 124:16-26.
30. Walton JD, Kattan DR, Thomas SK, Spengler BA, Guo H-F, Biedler JL, Cheung NKV, Ross RA. Characteristics of Stem Cells from Human Neuroblastoma Cell Lines and in Tumors. Neoplasia. 2004; 6: 838-45.
31. Thiele CJ. Neuroblastoma Cell Lines. Lancester, UK: Kluwer Academic Publishers; 1998. p. 21-53.
32. Khalili JS, Yu X, Wang J, Hayes BC, Davies MA, Lizee G, Esmaeli B, Woodman SE. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ-and GNA11-dependent manner. Clinical Cancer Research. 2012; 18: 4345-55.
33. Ma L, Teruya-Feldstein J, Bonner P, Bernardi R, Franz DN, Witte D, Cordon-Cardo C, Pandolfi PP. Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. Cancer Research. 2007; 67: 7106-12.
34. Aksamitiene E, Kiyatkin A, Kholodenko BN. Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance. Biochemical Society Transactions. 2012; 40: 139-46.
35. Chou T-C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacological Reviews. 2006; 58: 621-81.
36. Ji H. Lysis of Cultured Cells for Immunoprecipitation. Cold Spring Harbor Protocols. 2010; 2010: pdb.prot5466.